MedTrace Logo

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

NCT04579588 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Conditions

  • Corona Virus Infection
  • Flu Vaccine
  • Immunity

Interventions

BIOLOGICAL

Flu shot

All participants will receive a single shot of the flu vaccine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Sayantani Sindher, MD · Stanford University

Eligibility

Min Age
9 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04579588 on ClinicalTrials.gov